After nearly two decades in development, RNA therapeutics are now a clinical reality.
Shore Capital’s Healthcare Analyst, Tara Raveendran, discusses how the approval of these RNA-based therapeutics marks the start of the next chapter in what has been a rollercoaster ride for this novel drug class.
Tara Raveendran’s article was published in the October 2018 edition of MedNous, and is available to download here.
Healthcare Analyst, Research
+44 (0)20 7647 8142